Intratumoral androgen biosynthesis has been recognized as an essential factor of castration-resistant prostate cancer. The present study investigated the effects of curcumin on the inhibition of intracrine androgen synthesis in prostate cancer. 
Curcumin, which is extensively used as a source of spice or pigment in curry and other foods in the Asian diet, is under clinical trial for various cancers and related diseases. 3 In cultured cell analyses, curcumin has been shown to cause apoptosis and cell cycle arrest with inhibited cell growth in prostate cancer cells. [4] [5] [6] Previously, we conducted a doubleblind placebo-controlled clinical trial to evaluate the effects of soy isoflavone and curcumin on serum prostate specific antigen (PSA) levels in male patients with negative prostate cancer biopsies. 7 In that clinical trial, PSA levels decreased in the patients among the group which PSA > 10 and treated with supplement containing isoflavones and curcumin (P = .01). Furthermore, curcumin treatment strongly inhibited PSA production and suppressed expression of the androgen receptor in cultured LNCaP prostate cancer cells. 7 These results were used to evaluate the potential efficacy of curcumin as a prostate cancer preventive and therapeutic agent because prostate cancer has a strong association with androgens. In addition, many of curcumin's biological effects involve key components of signal transduction pathways within cancer cells, including prostate cancer cells. We previously reported that curcumin induces apoptosis through DNA damage response, which obstructs progression of various cancers. 6 We performed preliminary microarray analyses to examine changes in gene expression between curcumin-treated and curcumin-untreated LNCaP cells. Notably, we identified an mRNA of Aldo-Keto reductase 1C2 (AKR1C2) as being strongly induced by curcumin. 8 These human aldo-keto reductases (AKR) can convert potent sex hormones into their cognate inactive metabolites or vice versa.
AKR1C2 is 1 of 4 AKR1C subfamily members that has unique substrate specificity and tissue distribution, despite sharing >84% sequence identity. 9 Selective reduction occurred for the gene expression of AKR1C2
and AKR1C1, but not AKR1C3, in prostate tumor samples compared with that of their paired benign tissue. 10 In prostate cells, AKR1C2 acts as a 3-ketosteroid reductase to decrease the dihydrotestosterone (DHT) level and prevents activation of the androgen receptor. Ji et al 11 suggest
that selective loss of AKR1C2 in prostate cancer may promote clonal expansion of tumor cells by the enhancement of androgen-dependent cellular proliferation through reduced DHT metabolism.
In the present study, we investigated the effect of curcumin on steroidogenesis in prostate cancer. We observed that curcumin significantly decreased testosterone and DHT levels, thereby suppress- (Hitachi, Tokyo, Japan). We then added 100 lL of Caspase-Glo 3/7
Reagent to each well and incubated for 1 h at room temperature.
We measured luminescence (relative luminescence units [RLU]) for apoptosis using Luminometer AB-2350 (Atto, Tokyo, Japan). DHT-picolinoyl. 14 The limits of quantification were 1 pg for testosterone and DHT.
|

| Statistical analysis
Data are expressed as mean AE SEM. For statistical analysis, we used 1-way ANOVA tests (SPSS). **P < .01 was considered significant.
3 | RESULTS
| Growth inhibition in prostate cancer cell lines by curcumin
We examined the effects of curcumin on the proliferation of both
LNCaP and 22Rv1 cells that express androgen receptors. Curcumin inhibited the growth of these cells in a dose-dependent manner. Figure 1A shows that cell viability of LNCaP decreased by 50% when 5 lmol/L of curcumin was added to the culture medium. nenolone. 18 The HSD3B2 expression was decreased. CYP17A1 was expressed at a very low level but increased after treatment with curcumin. We examined the protein expression of SRD5A1 and SRD5A2, which convert testosterone to DHT. The expression of SRD5A2 was unaffected by the treatment of curcumin. The result showed that SRD5A1 expression in LNCaP cells was dose-dependently increased with curcumin (10 to 50 lmol/L) compared with control ( Figure 4A ). We also performed these analyses in another androgen receptor-positive prostate cancer cell line, 22Rv1, and similar results were obtained ( Figure 4B ).
3.6 | Testosterone and dihydrotestosterone levels in mouse prostate tissues after curcumin treatment Figure 5A ). Nevertheless, the DHT concentration was not decreased ( Figure 5B ). 25 We studied the effect of curcumin on the proliferation of other cancer cell lines, such as T24 and RT4 bladder cancer cells, by MTS assay. Although at the concentration of 50 lmol/L curcumin demonstrated suppression of cell proliferation, the degree of growth suppression in bladder cancer cells was lower compared with prostate cancer cells. As we previously, reported curcumin also induces DNA damage response to suppress the cell growth, and we suppose that this signaling pathway may be involved in bladder cancer cells. 6 In LNCaP, cDNA microarray analysis identified AKR1C2 as a factor in androgen metabolism and verified that curcumin increases its expression. In the prostate, DHT is predominantly metabolized by AKR1C2. 9,10 AKR1C2 is highly expressed in human prostate. 26 Compared to the paired benign tissues, prostate cancer tissues showed reduced metabolism of DHT, which corresponded with a loss of AKR1C2 expression. 10 Intraprostatic androgen levels in castrated male patients with locally recurrent CRPC are further elevated relative to serum levels, while testosterone levels in tissues in metastatic CRPC may actually be higher than in the prostate prior to castration. 23, [27] [28] [29] Moreover, the recent study showed that the high testosterone levels in prostate tissue had a good correlation with high Gleason scores and advanced clinical stages. 30 The presence of significant amounts of testosterone in the tissues of recurrent prostate cancers may be due to endogenous synthesis of androgens from adrenal steroid precursors or cholesterol. 29 It could be deduced from the current study that curcumin may reduce testosterone in these prostate cancer cells through the reduction of expressions of testosterone synthesizing proteins, because in LNCaP, the expression of StAR, CYP11A1 and HSD3B2 were significantly decreased. A decrease in testosterone concentration in the prostate was observed in both in vitro and in vivo analysis when AKR1C2 expression was increased by curcumin administration. However, the concentration of DHT, which has higher androgen activity than testosterone, remained unchanged in an in vivo model. One possible reason is that DHT synthesis through HSD17B10 may be able to convert 5a-androstanediol into DHT in vivo. 31 Further studies should be conducted in different prostate cancer mouse models.
The current study is the first report of a curcumin-facilitated reduction in intracellular prostate testosterone. As curcumin reduces testosterone activity in LNCaP and prostate cancer model TRAMP, it may have a role in inhibiting cancer onset and growth. Collectively, our studies suggest that curcumin can directly and indirectly regulate the intracellular activity of androgen signaling, thereby providing new therapeutic targets for prostate cancer. The combination of docetaxel and curcumin in patients with CRPC was well tolerated in a phase II study; and a randomized trial is pending. 32 As a new molecular targeted therapy, combination therapy of curcumin with some of the enzyme inhibitors of testosterone metabolism may allow lower doses of these inhibitors for improved efficacy and decreased side effects.
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